Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Norbert Pardi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $628,499 — ABSTRACT The remarkable effectiveness of the COVID-19 mRNA vaccines heralds a transformative immunization platform against viral infections. A key innovation—recognized with the 2023 Nobel Prize—is the replacement of uridine (U) with N1-methylpseudouridine (m1Ψ) in their mRNA constructs. This substi…
Yogesh K Gupta · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $172,636 — ABSTRACT The massive global pandemic with high morbidity and mortality makes Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) one of the deadliest viruses in recent history. It is especially noteworthy for hijacking the normal operations of human cells. To develop effective therapies, we…
Elias Sayour · UNIVERSITY OF FLORIDA · 2024 · $601,230 — Project Summary While activated T cells cross the blood-brain barrier (BBB), immunotherapy has yet to be harnessed for targeted therapy due to GBM’s heterogeneity and immunosuppressive microenvironment. Unleashing immunotherapy against GBM requires new technologies that activate the tumor microenvir…
Xiaobo Zhou · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2024 · $351,000 — The COVID-19 pandemic has presented new challenges to individuals world-wide. Since the first reports of infections in the US more than 90 million individuals have become infected and more than 1 million have died. SARS-CoV-2 genome has various open reading frames (ORFs) encoding 16 non-structural p…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2024 · $226,500 — Abstract Cryptococcal meningoencephalitis is responsible for 15% of the total deaths of AIDS patients. There is no vaccine available for cryptococcosis and the disease claims hundreds of thousands of lives each year, with the global mortality rates of ~70% despite current antifungal therapies. The …
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2024 · $879,161 — PROJECT SUMMARY (See instructions): A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we leverage three recent discoveries from our groups to generate more effective V2 apex immunogens. Having found that unshielded regions (“glycan hol…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2024 · $577,453 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Laurie Ann Rumker · HARVARD MEDICAL SCHOOL · 2024 · $46,918 — Project Summary/Abstract Tuberculosis (TB) remains the global leading cause of death from an infectious agent. Understanding why some patients present with early symptoms while others develop latent infections is critical for combating this illness. While environmental factors are known to elevate …
Gaurav Sahay · OREGON STATE UNIVERSITY · 2024 · $625,649 — ABSTRACT Inherited retinal dystrophies (IRDs) are a heterogenous group of orphan diseases, inherited in an autosomal dominant, recessive or X-linked pattern in addition to mitochondrial transmission, all leading to the loss of functional vision and often progressing to blindness. As a group, IRDs ar…
Thomas Siegmund Postler · INTERNATIONAL AIDS VACCINE INITIATIVE · 2024 · $448,768 — Project Summary/Abstract Tuberculosis remains one of the top ten leading causes of death worldwide (1). Based on the most current information from WHO 2020 report, in 2019 an estimated 1.4 million people died from TB and approximately 10,000,000 fell ill (2). The COVID-19 pandemic has led to massive…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2024 · $812,498 — Abstract Genital herpes affects 650 million people globally. Vaccines are urgently needed to prevent infection and treat individuals already infected. During the current funding cycle, we developed a candidate vaccine for preventing genital herpes that uses nucleoside-modified mRNA encapsulated wit…
ROBERT J FONTANA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $374,400 — ABSTRACT Over the past 5 years, the DILIN Prospective and Retrospective studies have led to significant improvements in DILI causality assessment (e.g. RECAM, HCV/ HEV testing) and improved understanding of the risk factors and outcomes of DILI due to individual drugs and HDS products. Mechanistic i…
Peter Shen · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $678,119 — PROJECT SUMMARY/ABSTRACT Although smallpox was formally declared to have been eradicated in 1980, molluscum contagiosum is widespread and a variety of zoonotic poxviruses continually infect and adapt to humans. This is exemplified by monkeypox/Mpox virus, which causes outbreaks in humans with increa…
Adam Tuttle · ENTERX BIOSCIENCES, INC. · 2024 · $294,052 — Project Summary Inherited retinal diseases (IRDs) are a heterogeneous group of genetic diseases that lead to loss of vision and often progress to blindness. As a group, IRDs are linked to over 280 genes and affect ~4.5 million people worldwide. In all IRDs, the ultimate cause of vision loss is degen…
SANJAY RAM · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $208,392 — PROJECT SUMMARY/ABSTRACT About 87 million new cases of gonorrhea occur worldwide annually. In 2020, 677,769 cases were reported to the CDC, a 111% increase in annual incidence since the historic low in 2009. Neisseria gonorrhoeae (Ng) has become resistant to almost every antibiotic in clinical use. …
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2024 · $538,330 — PROJECT SUMMARY Cancer vaccines have significantly advanced cancer immunotherapy; and recent successes of mRNA vaccines have raised prospect of generating potent anti-tumor response by specifically delivering mRNAs encoding tumor-associated antigens to antigen presenting cells (APCs). However, APC a…
Olivia Selfridge Rissland · FEDERATION OF AMER SOC FOR EXPER BIOLOGY · 2024 · $5,000 — PROJECT SUMMARY A counterbalance to RNA synthesis, RNA degradation is critical for regulating gene expression. The understanding that RNA degradation is critical for gene expression traces back to 1959 when Pardee, Jacob and Monod demonstrated in a historical paper that there had to be an unstable i…
Karl Munger · TUFTS UNIVERSITY BOSTON · 2024 · $418,426 — Despite the currently available effective prophylactic vaccines, human papilloma virus infections remain the most common cause of venereal disease. Human papilloma virus-associated diseases are particularly prevalent in medically underserved segments of the population. Despite decades of research, t…
John H Adams · UNIVERSITY OF SOUTH FLORIDA · 2024 · $965,047 — Project Summary/Abstract Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of Africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from P. vivax than P. falciparum. …
Ian J Mohr · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $436,140 — 7. PROJECT SUMMARY / ABSTRACT Regulation of gene expression at the level of translation allows cells and organisms to respond swiftly to physiological stress and changing environments. Indeed, differential translation of capped, polyadenylated mRNAs by eukaryotic ribosomes plays a critical role in b…